FDA approves GSK's Jemperli as first immunotherapy for MSI-H/DMMR rectal cancer
GSK•The FDA approved GSK's Jemperli as the first immunotherapy for MSI-H/DMMR locally advanced rectal cancer. GSK said no disease recurrences were reported among responders after a two-year median follow-up.
1. FDA approval
The FDA approved GSK's Jemperli as the first immunotherapy for MSI-H/DMMR locally advanced rectal cancer. GSK said no disease recurrences were reported among responders after a two-year median follow-up.
